Korys, FPIM et al. in €12m extended series-B for Remynd

The company, which is working on diseases caused by cellular dysfunction, received additional funding of €12m, having initially raised €12m in December 2018.

Remynd will use the funding to complete proof-of-concept clinical trials for both its Alzheimer's and diabetes programmes in 2022.

The company initiated a first-in-human trial of RES19-T for the treatment of Alzheimer's in 2020 and expects to launch a first-in-human trial in diabetes this year.

Previous funding
In December 2018, the company raised €12m in an initial series-B round co-led by Korys and PMV, with participation from existing shareholders including BNP Paribas Fortis, KU Leuven, Gemma-Frisius Fund and Dr Bernard Majoie of Fondation Fournier-Majoie.

Company
Founded in 2002 and based in Heverlee, Remynd is a clinical-stage biotechnology company developing treatments for Alzheimer's, diabetes and other diseases caused by cellular dysfunction. It has around 50 employees, according to its Linkedin page.

People
Remynd – Staph Leavenworth Bakali (chairman); Koen De Witte (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Benelux
• Belgium
• BNP Paribas
• Venture
• healthcare